Loading clinical trials...
Loading clinical trials...
TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Taejoon Pharmaceutical Co., Ltd.
NCT07462000 · Primary Open-Angle Glaucoma (POAG), Cataract
NCT07217678 · Glaucoma, Open-Angle Glaucoma, and more
NCT07390890 · Primary Open Angle Glaucoma, Ocular Hypertension
NCT05902871 · Primary Open Angle Glaucoma, Ocular Hypertension, and more
NCT07218796 · Cataract, Glaucoma, and more
Chan Yun, Kim
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions